following a full submission assessed under the ultra-orphan medicine process:
letermovir (Prevymis®) is accepted for use within NHSScotland.
Indication under review: for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
Letermovir, compared with placebo, reduced the incidence of CMV reactivation and disease in CMV-seropositive adults undergoing allogeneic HSCT.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of letermovir. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- letermovir (Prevymis)
- SMC ID:
- Prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 11 March 2019